Proteomics International Laboratories (ASX:PIQ) subsidiary OxiDx's diagnostic testing technology showed a potential to identify muscle damage and recovery among athletes via a finger prick blood test, according to a Tuesday filing with the Australian bourse.
Based on a study of 20 marathon runners, the OxiDx diagnostic test was able to measure and assess exercise-induced muscle damage, the filing said.
Results were published in the Physiological Reports journal.